Selected Publications
Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, Haun PL, Vittorio CC, Rook AH, Kim EJ, Samimi SS.: Usage and safety of topical tacrolimus in patients with mycosis fungoides Clin Exp Dermatol. : 2022.
Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS.: Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol J Invest Dermatol. 142 (2): 493-496,2022.
Lewis DJ, Rook AH.: Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations Int J Dermatol. 60 (9): e362-e364,2021.
Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ.: Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome JAMA Dermatol. 157 (3): 317-321,2021.
Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC: Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma Leuk Lymphoma (20): 1-22,2015.
Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.: Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 20 : 1-22,2015.
Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158 (1): 1-7,2015.
Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.: Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 17 (2): 78-84,2014.
Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.: CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. J Invest Dermatol 134 : 229-36,2014.
Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ.: Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149 (5): 2013.
Academic Contact Information
Department of Dermatology
3400 Civic Center Boulevard
Perelman Center for Advanced Medicine
Philadelphia, Pa. 19104
Philadelphia,
PA
19104
Phone: 215-662-7610
Patient appointments: 800-789-7366